Groundbreaking research into Fisher and Paykel’s Optiflow

Company News

by Rachael Jones

Fisher and Paykel’s (ASX:FPH) Optiflow nasal high flow therapy has shown significant benefits for children in new Australian research.

In what has been the world’s largest randomised controlled trial in nasal high flow therapy it shows that it can significantly lower rates of escalation of care for infants with bronchiolitis.

The research was carried out by a team at Lady Cilento Children’s hospital in Brisbane.

The study will help drive change in the use of the Optiflow nasal high flow therapy.

Shares in Fisher and Paykel’s (ASX:FPH) are trading 0.57 per cent lower to $12.22

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.